As the holiday season ramps up with parties, big meals and celebratory drinks, doctors are reminding men not to ignore their ...

I felt fine, but my Whoop data told a different story. Paying attention led to early detection and a successful treatment.

Vektor Medical receives US FDA 510(k) clearance for its next-generation vMap technology to enhance connectivity: San Diego Saturday, December 13, 2025, 17:00 Hrs [IST] Vektor Medi ...

BSX builds momentum in PFA as FARAPULSE posts strong growth, and new trial results and expanded FDA labeling boost its AF ...

Pirtobrutinib showed noninferiority in ORR compared to ibrutinib in BTK inhibitor-naive CLL/SLL patients, with a favorable PFS trend. Safety profiles indicated fewer adverse events with pirtobrutinib, ...

Contrary to old beliefs, a new study suggests daily coffee might help manage irregular heart rhythms like AFib. Researchers found participants drinkin ...

A routine blood test identified abnormalities, leading to follow-up tests. A hematologist diagnosed Evans with early-stage ...

The reversible BTK inhibitor was at least as effective as AbbVie/Johnson & Johnson's older, non-reversible drug Imbruvica ...

Pirtobrutinib significantly improved PFS in previously untreated patients with chronic lymphocytic leukemia and small lymphocytic lymphoma compared with a standard chemoimmunotherapy regimen in a ...

In a new trial, the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib increased the rate of survival without disease progression and was well tolerated with a more favorable safety profile when ...

Pirtobrutinib, a non-covalent Bruton tyrosine kinase (BTK) inhibitor, met the primary endpoint for non-inferiority in terms of overall response rate in the first head-to-head comparison with ibrutinib ...

Significant treatment options are changing the management of CLL, according to research presented at the ASH Annual Meeting 2025.